1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Granules India Limited

Granules India Limited

GRANULES.BO
Granules India LimitedIN flagBombay Stock Exchange
889.55
INR
+8.40
- -
220.50BMarket Cap
Granules India Limited
GRANULES.BO
(Bombay Stock Exchange)

Recent

price

889.55

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
23.69
32.6
38.05
54.19
63.43
65.58
64.42
67.65
87.93
100.11
128.25
150.39
183.22
185.38
183.83
219.56
219.46
Revenue per Share
1.04
1.49
1.62
3.72
4.46
5.95
7.52
5.49
9.3
13.19
22.05
16.65
21.05
16.73
20.69
24.47
24.46
Basic EPS, GAAP
1.18
-1.47
-1.26
-7.85
0.11
-0.52
-5.87
-18.5
-0.68
11.47
6.47
-2.65
13.37
2.43
12.16
9.67
- -
Free Cash Flow per Basic Share
0.15
0.17
0.23
0.23
0.41
1.13
1.02
1.2
1.21
1.21
0.99
1.5
0.76
1.5
1.5
1.5
- -
Dividend per Share
1.08
5.96
7.23
5.55
4.74
9.55
11
14.35
21.75
33.72
55.43
70.89
91.86
108.22
127.22
1.02
1.02
Book Value per Share
10.96
11.36
13.02
12.27
16.87
28
31.57
41.54
45.66
58.3
74.57
92.21
103.66
122.78
144.53
200.82
200.73
Tangible Book Value per Share
201
201
201
202
204
207
219
242
254
254
249
248
245
242
242
243
243
Basic Weighted Avg Shares
4,752
6,540
7,644
10,959
12,929
13,555
14,097
16,345
22,344
25,452
31,960
37,272
44,963
44,902
44,560
53,389
53,389
Sales/Revenue/Turnover
8.15
9.18
8.31
11.89
12.16
16.31
16.52
12.44
12.49
16.68
22.39
15.42
16.41
14.71
16.15
16.65
16.65
Operating Margin (%)
183
207
231
298
527
584
715
762
1,055
1,370
1,515
1,586
1,845
2,073
2,255
2,961
2,961
Depreciation Expense
209
300
326
752
909
1,230
1,645
1,326
2,364
3,354
5,495
4,128
5,166
4,053
5,015
5,950
5,950
Net Income, GAAP
21.9
30.3
29.7
33.05
28.96
32.87
28.38
32.35
27.37
25.65
21.99
26.03
24.82
25.93
24.03
24.2
24.2
Effective Tax Rate (%)
4.4
4.58
4.26
6.87
7.03
9.07
11.67
8.11
10.58
13.18
17.19
11.07
11.49
9.03
11.25
11.14
11.14
Profit Margin (%)
1,299
466
831
844
798
1,633
410
3,087
3,858
7,353
8,239
8,634
7,606
8,228
11,123
16,756
16,756
Working Capital
1,372
881
1,755
3,092
2,427
1,842
1,242
4,331
4,788
4,215
3,411
2,420
2,192
1,522
4,707
4,581
4,581
LT Debt
2,198
2,451
2,749
3,560
4,308
6,616
9,036
13,042
15,295
18,437
21,733
25,871
28,349
32,255
37,156
50,850
50,850
Total Equity
8.57
10.37
8.96
12.94
12.35
13.22
11.92
7.13
8.44
12.09
19.49
12.72
14.53
11.55
11.31
11.47
11.47
Return on Invested Capital (%)
18.77
16.23
11.25
17.55
18.09
19.88
22.01
13.45
17.56
21.35
28.38
16.55
17.37
12.51
13.69
22.44
22.44
Return on Capital (%)
96.11
42.39
24.6
58.42
87.03
83.7
75.12
45.14
52.57
47.58
49.09
26.3
25.76
16.63
17.58
38.28
38.28
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
13,303
- -
10,539
LT Borrowings
3,176
- -
2,972
LT Finance Leases
1,591
- -
1,610
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
243
- -
248
Market Capitalization
125,239
145,246
151,110

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
30,869
- -
37,676
Cash, Cash Equivalents & STI
6,257
- -
9,535
Accounts Receivable, Net
7,605
- -
9,094
Inventories
14,883
- -
16,730
Total Current Liabilities
24,173
- -
20,920
Payables & Accruals
- -
- -
- -
ST Debt
13,303
- -
10,539
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
23.11%
18.89%
36.86%
Free Cash Flow
-104.2%
-88.33%
-20.29%
Net Income, GAAP
21.95%
4.22%
18.64%
Sales/Revenue/Turnover
15.23%
11.23%
19.81%
Total Cash Common Dividend
10.73%
19.13%
0.12%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
9,855
11,880
11,497
11,596
44,902
2025
11,799
9,565
11,335
11,968
44,560
2026
12,088
12,947
13,780
14,574
53,389

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.98
4.22
5.18
- -
16.73
2025
5.56
4.01
4.85
6.27
20.69
2026
4.64
5.38
6.19
8.23
24.47

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1.5
2025
- -
- -
- -
- -
1.5
2026
- -
- -
- -
- -
1.5
Similar Companies
Zhuhai Rundu Pharmaceutical Co., Ltd. (002923.SZ)
Indivior Pharmaceuticals Inc (INDV)
Luoxin Pharmaceuticals Group Stock Co., Ltd. (002793.SZ)
Global Hemp Group Inc. (GHG.CN)
TherapeuticsMD, Inc. (TXMD)
CanSino Biologics Inc. (CASBF)
Business
Granules India Limited, a vertically integrated pharmaceutical manufacturing company headquartered in Hyderabad, India, and founded in 1984, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), and finished dosages (FDs) including tablets, caplets, press-fit capsules in bulk, blister packs and bottles; it specializes in large-volume off-patent drugs such as paracetamol, ibuprofen, metformin, guaifenesin, methocarbamol, and has expanded into oncology therapeutics, high potent APIs, peptide-based APIs including GLP-1 receptor agonists for anti-diabetic and anti-obesity treatments, multiple unit pellet systems (MUPS), and modified/delayed release technologies. The company operates 10 manufacturing facilities primarily in India including the world's largest PFI plant in Gagillapur, a joint venture facility in Wuhan, China, and advanced plants in Visakhapatnam for oncology and high potent products; it serves customers in over 80 countries with a focus on regulated markets like the US and Canada through subsidiaries in the US, UK, Colombia, and China, and provides contract research and manufacturing services (CRAM), contract development and manufacturing organization (CDMO) capabilities, and research through centers in Hyderabad and Pune. Granules India recently completed the acquisition of Senn Chemicals AG, a Switzerland-based peptide CDMO, through its wholly owned subsidiary Granules Peptides Private Limited in April 2025 for approximately Rs 192.5 crore to enter the high-growth peptide therapeutics segment; it incorporated a new wholly owned subsidiary, Granules Pharmaceuticals Canada Inc., in November 2025 via its US subsidiary to expand North American presence; received US FDA approval for a new finished dosage product at its Hyderabad facility enabling US launch; and inaugurated two Centres of Excellence at IIT Hyderabad's Technology Research Park in December 2025 for peptide development and particle engineering to enhance CDMO capabilities and proprietary technologies.